Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7420059 | 0.97 | NPSR1 (0.50) | NPSR1CYP4F2CYP4A11MAPTCYP3A4 | |
| SCHEMBL758201 | 0.97 | NPSR1 (0.50) | NPSR1CYP4F2CYP4A11MAPTCYP3A4 | |
| SCHEMBL990527 | 0.95 | — | — | |
| SCHEMBL390361 | 0.89 | — | — | |
| SCHEMBL34476145 | 0.81 | NPSR1 (0.37) | NPSR1CYP4F2CYP4A11KDM4ELMNA | |
| SCHEMBL2077252 | 0.81 | NPSR1 (0.37) | NPSR1CYP4F2CYP4A11CYP3A4KMT2A | |
| Hydrochloric Acid SCHEMBL2077250 | 0.80 | NPSR1 (0.36) | NPSR1CYP4F2CYP4A11KMT2AKDM4E | |
| SCHEMBL854175 | 0.78 | KDM4E (0.41) | NPSR1CYP4F2CYP4A11CYP3A4KMT2A | |
| SCHEMBL17027474 | 0.78 | NPSR1 (0.38) | NPSR1CYP4F2CYP4A11LMNA | |
| SCHEMBL15125365 | 0.78 | CYP3A4 (0.42) | NPSR1CYP4F2CYP4A11CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143195-B1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| EP-3541804-B1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-02 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| CN-115884810-A | Imidazopyridazines as IL-17 modulators | 詹森药业有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20230081548-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-16 | — | — | US | disclosed |
| US-20220402922-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2022-12-22 | — | — | US | disclosed |
| EP-3184512-B1 | ANESTHETIC COMPOUNDS AND RELATED METHODS OF USE | MASSACHUSETTS GEN HOSPITAL (US) | 2020-12-23 | — | — | EP | disclosed |
| US-6265404-B1 | FACTOR X INHIBITOR | BERLEX LABORATORIES, INC. | 2001-07-24 | — | — | US | disclosed |
| US-6232325-B1 | THROMBOSIS THERAPY | BERLEX LABORATORIES, INC. | 2001-05-15 | — | — | US | disclosed |
| US-6177473-B1 | FACTOR X INHIBITOR | BERLEX LABORATORIES, INC. | 2001-01-23 | — | — | US | disclosed |
| US-6130225-A | Substituted p-trifluoromethylphenyluracils | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-10 | — | — | US | disclosed |
| US-6008234-A | TREATING A HUMAN HAVING A DISEASE-STATE CHARACTERIZED BY THROMBOTIC ACTIVITY, INHIBITING HUMAN BLOOD COAGULATION FACTOR XA | BERLEX LABORATORIES, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| CN-1234798-A | Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxycarboxylic acid derivatives and their use as anticoagulants | SCHERING AG (DE) | 1999-11-10 | — | — | CN | disclosed |
| EP-0929547-A1 | BENZAMIDINE DERIVATIVES SUBSTITUTED BY CYCLIC AMINO ACID OR CYCL IC HYDROXY ACID DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-07-21 | — | — | EP | disclosed |
| EP-0923562-A1 | SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS | BAYER AG (DE) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998011094-A1 | BENZAMIDINE DERIVATIVES SUBSTITUTED BY CYCLIC AMINO ACID OR CYCL IC HYDROXY ACID DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998006706-A1 | SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | NPSR1 994/4885CYP4F2 167/4885CYP4A11 86/4885 |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | NPSR1 994/4885CYP4F2 167/4885CYP4A11 86/4885 |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | NPSR1 994/4885CYP4F2 167/4885CYP4A11 86/4885 |
| US-20230081548-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | NPSR1 994/4885CYP4F2 167/4885CYP4A11 86/4885 |
| US-20220402922-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | NPSR1 994/4885CYP4F2 167/4885CYP4A11 86/4885 |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | NPSR1 994/4885CYP4F2 167/4885CYP4A11 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.